



Inologic Awarded National Institutes of Health Funded Research Grant

SEATTLE, Washington, November 6, 2002 -- Inologic, Inc. announced today that it was awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute.

Inologic is researching an entirely new class of drugs for the treatment of cystic fibrosis (CF). Inologic's compounds are expected to remediate the underlying genetic defect involved in CF and restore normal function to mucous membranes by regulating the activity of alternate ion channels. The \$97,000 grant was awarded to study the cellular effects of Inologic's drugs for the treatment of CF. This is the third SBIR grant the company has received. These grants have totaled \$1.35 million in funding.

"Our goal is to develop a CF drug candidate that will act to restore normal fluid secretion at the cellular level and hopefully reduce the infections and mucus buildups experienced by CF patients. We are pleased to have the support of the NIH as we perform further research on our compounds," stated Ed Field, President and Chief Executive Officer of Inologic.

About Inologic

Inologic, Inc. is the leading biopharmaceutical company in the discovery and development of a new class of therapeutics based on inomics – the study of inositol signaling molecules and their role in regulating key cell functions. Inologic believes its proprietary compounds can affect the signaling pathways that manage the cell functions linked to many serious diseases, including inflammation, cancer, diabetes, central nervous system disorders, cystic fibrosis, and diarrhea. Inologic will initially focus its development efforts on the advancement of compounds to treat inflammation and cystic fibrosis.

For more information on Inologic, please visit <http://www.inologic.com> or contact Ed Field, President and Chief Executive Officer at 206.448.9226.